These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 16797800)
21. Pharmacokinetics of oseltamivir in young and very elderly subjects. Abe M; Smith J; Urae A; Barrett J; Kinoshita H; Rayner CR Ann Pharmacother; 2006 Oct; 40(10):1724-30. PubMed ID: 16940405 [TBL] [Abstract][Full Text] [Related]
22. [Can oseltamivir (Tamiflu) be used in dialysis-requiring renal failure?]. Rosenborg S Lakartidningen; 2010 Jan 20-26; 107(3):116-7. PubMed ID: 20225688 [No Abstract] [Full Text] [Related]
23. Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers. Hassan Y; Alfadly SO; Azmin MN; Peh KK; Tan TF; Noorizan AA; Ismail O Singapore Med J; 2007 Sep; 48(9):819-23. PubMed ID: 17728962 [TBL] [Abstract][Full Text] [Related]
24. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Shah J; Wesnes KA; Kovelesky RA; Henney HR Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304 [TBL] [Abstract][Full Text] [Related]
25. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects. Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405 [TBL] [Abstract][Full Text] [Related]
26. Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan. Uchimura N; Kuwahara H; Kumagai Y; Mishima K; Inoue Y; Rayner CR; Toovey S; Davies BE; Hosaka Y; Abe M; Prinssen EP Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):309-14. PubMed ID: 21592308 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers. Mendoza L; Hajdúch M; Plausinaitis R; Platílová V; Emritte N; Svoboda M Pharmazie; 2006 Sep; 61(9):805-6. PubMed ID: 17020163 [TBL] [Abstract][Full Text] [Related]
29. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Dutkowski R; Smith JR; Davies BE Int J Antimicrob Agents; 2010 May; 35(5):461-7. PubMed ID: 20189775 [TBL] [Abstract][Full Text] [Related]
30. Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Ogihara T; Kano T; Wagatsuma T; Wada S; Yabuuchi H; Enomoto S; Morimoto K; Shirasaka Y; Kobayashi S; Tamai I Drug Metab Dispos; 2009 Aug; 37(8):1676-81. PubMed ID: 19439487 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833 [TBL] [Abstract][Full Text] [Related]
32. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice. Hatori A; Arai T; Yanamoto K; Yamasaki T; Kawamura K; Yui J; Konno F; Nakao R; Suzuki K; Zhang MR Nucl Med Biol; 2009 Jan; 36(1):47-55. PubMed ID: 19181268 [TBL] [Abstract][Full Text] [Related]
33. Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study. Bockbrader HN; Alvey CW; Corrigan BW; Radulovic LL Int J Clin Pharmacol Ther; 2013 Mar; 51(3):244-8. PubMed ID: 23357837 [TBL] [Abstract][Full Text] [Related]
34. Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers. Jang K; Kim MK; Oh J; Lee S; Cho JY; Yu KS; Choi TK; Lee SH; Lim KS Drug Des Devel Ther; 2017; 11():705-711. PubMed ID: 28331290 [TBL] [Abstract][Full Text] [Related]
35. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495 [TBL] [Abstract][Full Text] [Related]
36. Cyclosporine bioavailability of two physically different oral formulations. Postolache P; Petrescu O; Dorneanu V; Zanini AC Eur Rev Med Pharmacol Sci; 2002; 6(6):127-31. PubMed ID: 12776806 [TBL] [Abstract][Full Text] [Related]
37. Oseltamivir and its active metabolite cross the placenta at significant levels. Meijer WJ; Bruinse HW; van den Broek MP; Kromdijk W; Wensing AM Clin Infect Dis; 2012 Jun; 54(11):1676-7. PubMed ID: 22460968 [No Abstract] [Full Text] [Related]
38. Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model. Berveiller P; Mir O; Vinot C; Bonati C; Duchene P; Giraud C; Gil S; Treluyer JM Am J Obstet Gynecol; 2012 Jan; 206(1):92.e1-6. PubMed ID: 21958869 [TBL] [Abstract][Full Text] [Related]
39. Design and evaluation of oseltamivir phosphate dual-phase extended-release tablets for the treatment of influenza. Yu L; Huang X; Jiang M; Guo W; Li X; Huang F; You J Int J Pharm; 2024 Aug; 661():124364. PubMed ID: 38914352 [TBL] [Abstract][Full Text] [Related]
40. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. Atiee G; Lasseter K; Baughman S; McCullough A; Collis P; Hollister A; Hernandez J J Clin Pharmacol; 2012 Sep; 52(9):1410-9. PubMed ID: 21960669 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]